In the future, it is necessary to establish humanized models that integrate diabetes comorbidities (insulin resistance, lipid metabolism disorders), conduct phase III clinical trials lasting ≥1 year with renal histopathological endpoints, and directly compare the efficacy of sGC activators and stimulators at different stages of DKD. This evidence concerns the gene SGCB and Disorder of lipid metabolism.